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Abstract
Aims/hypothesis Pancreatic beta cell dysfunction is a
prerequisite for the development of type 2 diabetes. Histone
deacetylases (HDACs) may affect pancreatic endocrine
function and glucose homeostasis through alterations in gene
regulation. Our aim was to investigate the role of HDAC7 in
human and rat pancreatic islets and clonal INS-1 beta cells
(INS-1832/13).
Methods To explore the role of HDAC7 in pancreatic islets
and clonal beta cells, we used RNA sequencing, mitochon-
drial functional analyses, microarray techniques, and HDAC
inhibitors MC1568 and trichostatin A.
Results Using RNA sequencing, we found increased HDAC7
expression in human pancreatic islets from type 2 diabetic com-
pared with non-diabetic donors. HDAC7 expression correlated
negatively with insulin secretion in human islets. To mimic the
situation in type 2 diabetic islets, we overexpressed Hdac7 in
rat islets and clonal beta cells. In both, Hdac7 overexpression
resulted in impaired glucose-stimulated insulin secretion.
Furthermore, it reduced insulin content, mitochondrial respira-
tion and cellular ATP levels in clonal beta cells. Overexpression
of Hdac7 also led to changes in the genome-wide gene expres-
sion pattern, including increased expression of Tcf7l2 and de-
creased expression of gene sets regulating DNA replication and
repair as well as nucleotide metabolism. In accordance, Hdac7
overexpression reduced the number of beta cells owing to en-
hanced apoptosis. Finally, we found that inhibiting HDAC7
activity with pharmacological inhibitors or small interfering
RNA-mediated knockdown restored glucose-stimulated insulin
secretion in beta cells that were overexpressing Hdac7.
Conclusions/interpretation Taken together, these results indi-
cate that increased HDAC7 levels caused beta cell dysfunction
and may thereby contribute to defects seen in type 2 diabetic
islets. Our study supports HDAC7 inhibitors as a therapeutic
option for the treatment of type 2 diabetes.
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Data from genome-wide association studies point towards
pancreatic beta cell dysfunction as a key defect causing type
2 diabetes [1]. However, the genetic variants identified so far
only explain a modest proportion of the estimated heritability
of type 2 diabetes, implying that additional factors remain to
be discovered [2]. These may include epigenetic mechanisms.
Indeed, we and others have identified epigenetic modifica-
tions in pancreatic islets, adipose tissue, skeletal muscle and
liver from individuals with type 2 diabetes that might be
important in the disease pathogenesis [3–8]. Numerous
enzymes, including histone deacetylases (HDACs), regulate
epigenetic modifications and may thereby affect gene expres-
sion and cellular function. A growing body of evidence sug-
gests that HDACs control mammalian pancreatic endocrine
cell function and glucose homeostasis [9–11]. For example,
mice lacking Hdac5 exhibit increased beta cell mass [9]. We
recently reported decreased DNA methylation and increased
gene expression of HDAC7 in pancreatic islets from human
donors with type 2 diabetes [3]. However, the role of HDAC7
in beta cells has not been explored. In the present study, we
investigated the functional consequences of Hdac7
overexpression in beta cells and islets in an effort to dissect
its potential role in diabetic islets.
Methods
RNA sequencing Pancreatic islets from 85 non-diabetic and
16 type 2 diabetic donors were obtained from the Human
Tissue Lab at EXODIAB/Lund University Diabetes Centre
th rough the Nord ic Ne twork fo r Cl in ica l I s l e t
Transplantation. The selection criteria for non-diabetic donors
were no diagnosis of type 2 diabetes and an HbA1c level
below 6.0% (52 mmol/mol), as determined by the Mono-S
method. The clinical characteristics of the islet donors are
shown in Table 1. Parts of this islet cohort have been described
previously [12]. High-quality RNA extracted from human
islets was used for sequencing with the TruSeq RNA sample
preparation kit (Illumina, San Diego, CA, USA) as previously
described [12]. This study was approved by the local ethics
committee. Informed consent was obtained from pancreatic
donors or their relatives.
Rat islet isolation and culture Pancreatic islets from 8- to 10-
week-old male Wistar rats (Taconic, Lille Skensved,
Denmark) were isolated by collagenase digestion and
hand-picked under a stereo microscope [13]. The isolated
islets were precultured for 24 h before adenoviral transduction
in RPMI 1640 with UltraGlutamine (Lonza, Vallensbaek,
Denmark) supplemented with 10% newborn calf serum
(Biological Industries, Kibbutz Beit Haemek, Israel),
100 U/ml penicillin and 100 μg/ml streptomycin (Life
Technologies, Paisley, UK) in 5% CO2 at 37°C. All animal
experiments were approved by the local ethics committee
and performed in accordance with the Guide for the Care
and Use of Laboratory Animals [14].
Overexpression of Hdac7 in rat islets and clonal beta cells
An adenoviral vector for Hdac7 overexpression, Ad-GFP-
CMV-ratHdac7, and a control vector conferring only green
fluorescent protein expression, Ad-GFP-CMV, were made
by Vector Biolabs (Philadelphia, PA, USA). Isolated rat
islets were infected with 50,000 virus particles/islet. The
rat clonal beta cell line INS-1 832/13 was transfected with
a pcDNA3.1 expression vector containing the cDNA
sequence of rat Hdac7 (Genscript, Piscataway, NJ, USA)
or the empty vector (control) by using Lipofectamine LTX
(Life Technologies). Experiments were performed 48 h
after transduction/transfection, unless stated otherwise.
PCR and western blot mRNA expression of Hdac7 and
Tcf7l2 was analysed using TaqMan assays and related to
expression of Ppia (Life Technologies) by quantitative
real-time (q)PCR and the ΔΔCt method. To verify overex-
pression of HDAC7 protein, clonal beta cells were transfected
with haemagglutinin-tagged cDNA for Hdac7 and lysed in
Table 1 Characteristics of hu-





Male/female (n) 52/33 10/6
HbA1c (%) 5.5±0.4 6.9±1.0 <0.0001
HbA1c (mmol/mol) 46.5±3.6 60.3±10.4 <0.0001
Age (years) 56.1±11.1 59.9±11.6 0.24
BMI (kg/m2) 25.6±3.1 28.2±4.3 0.03
GSIS (ng islet–1 h–1) at 16.7 mmol/l glucose 0.92±0.95 0.42±0.36 0.05
Data are presented as means ± SD, unless otherwise indicated
The Mann–Whitney U test was used for statistical analysis
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RIPA buffer (50 mmol/l Tris, pH 7.6, 150 mmol/l NaCl, 0.1%
SDS, 0.5% sodium deoxycholate, 1% Triton-X100, protease
inhibitor cocktail; Sigma-Aldrich, St Louis, MO, USA), and
boiled with sample buffer (60 mmol/l Tris, pH 6.8, 10%
glycerol, 2% SDS, 10% β-mercaptoethanol, bromophenol
blue). Samples were separated on Mini-PROTEAN TGX gels
(Bio-Rad, Hercules, CA, USA) and transferred onto
Hybond-LFP PVDF membranes (GE Heal thcare,
Piscataway, NJ, USA). Protein expression was detected using
a rabbit haemagglutinin tag (Abcam, Cambridge, UK; diluted
1:4000) and mouse β-actin (Sigma-Aldrich; diluted 1:10,000)
antibodies, and secondary DyLight 680/800 conjugated goat
antibodies (Thermo Scientific, Rockford, IL, USA; diluted
1:15,000), all validated by the respective suppliers. Blots were
scanned using an Odyssey imaging system (LI-COR, Lincoln,
NE, USA).
Insulin secretion and content Glucose-stimulated insulin
secretion (GSIS) was examined in isolated rat islets. For each
condition (Hdac7 overexpression and control), 24 islets (three
islets per well) were transferred to Krebs–Ringer HEPES
buffer (115 mmol/l NaCl, 4.7 mmol/l KCl, 2.6 mmol/l
CaCl2, 1.2 mmol/l KH2PO4, 1.2 mmol/l MgSO4, 10 mmol/l
HEPES, 0.2% BSA, 2 mmol/l glutamine, 5 mmol/l NaHCO3,
100 U/ml penicillin, 100 μg/ml streptomycin, pH 7.4)
containing 2.8 mmol/l glucose and incubated 30 min prior to
the GSIS experiment. Islets were then exposed to basal
(2.8 mmol/l) or stimulatory (16.7 mmol/l) glucose for
60 min. The buffer was then collected and insulin secretion
was determined using ELISA (Mercodia, Uppsala, Sweden)
and normalised to insulin content.
Insulin secretion was also measured in transfected clonal
beta cells at 2.8 and 16.7 mmol/l glucose levels in a secretion
assay buffer (SAB) with normal (5.9 mmol/l) as well as
elevated (35 mmol/l) K+ concentrations, as previously
described [15]. In addition, two HDAC inhibitors, MC1568
(1 μmol/l; Sigma-Aldrich) [16] and trichostatin A (TSA)
(0.625 μmol/l; Sigma-Aldrich) [17] were added to the culture
medium 24 h before secretion experiments, as indicated.
Insulin was measured in the supernatant fraction using an
insulin RIA (Siemens Diagnostics, Erlangen, Germany) or
insulin ELISA and normalised to total protein, as determined
by a bicinchoninic acid assay (Thermo Scientific). Total
insulin content was determined after acid ethanol extraction
and normalised to protein content.
Mitochondrial respiration The Extracellular Flux Analyzer
XF24 (Seahorse Bioscience, North Billerica, MA, USA) was
used to monitor the oxygen consumption rate (OCR) as
described elsewhere [18]. Clonal beta cells were cultured
and transfected as above on XF24 microplates coated with
poly-D-lysine (10 μg/ml) at 200,000 cells/well prior to
analysis. Data were normalised to total protein.
ATP measurement Clonal beta cells were starved for 2 h in
SAB containing 2.8 mmol/l glucose. Next, the cells were
treated with SAB containing either 2.8 or 16.7 mmol/l glucose
for 15 min, washed in PBS, lysed in water and kept on dry ice
for 15 min. Lysates were thawed, sonicated for 15 s and used
for ATP and total protein measurements. The level of ATPwas
monitored using an ATP Kit SL (BioThema, Handen,
Sweden) according to the manufacturer’s instructions.
Microarray mRNA expression analysis RNAwas extracted
from transfected clonal beta cells and the quantity and quality
were assessed using the NanoDrop spectrophotometer
ND-1000 (Thermo Fisher Scientific, Wilmington, DE, USA)
and 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA),
respectively. Whole-transcript microarray analysis was
conducted on the WT Gene 2.0 ST Array (Affymetrix, Santa
Clara, CA, USA) by the Swegene Center for Integrative
Biology at Lund University. mRNA expression data were
obtained from a total of 30,619 probe sets, representing
20,173 annotated transcripts and 19,603 unique genes. The
Robust Multi-array Average method was used for background
correction, data normalisation and probe summarisation.
Gene Set Enrichment Analysis Gene Set Enrichment
Analysis (GSEA) [19, 20] (www.broad.mit.edu/GSEA)
version 4.0 was used to identify enriched gene sets of the
microarray data using the Kyoto Encyclopedia of Genes and
Genomes (KEGG). Probe sets pertaining to transcripts were
ranked based on t statistics values from paired t tests.
Cell number, apoptosis and proliferation assays Clonal
beta cells were seeded and transfected on 96-well plates.
Cell number was determined by crystal violet staining, as
previously described [3]. Caspase-3 and -7 activity as a
measure of apoptosis were assessed using Apo-ONE
Homogeneous Caspase-3/7 Assay (Promega, Madison, WI,
USA) according to the manufacturer’s protocol. Cell prolife-
ration was measured with the Cell Proliferation ELISA, BrdU
kit (Roche Applied Sciences, Mannheim, Germany). BrdU
labe l l ing so lu t ion was added to the ce l l s 24 h
post-transfection and cells were cultured for another 24 h prior
to absorbance measurement with a Tecan Infinite M200 Pro
plate reader (Tecan Group, Männedorf, Switzerland).
Silencing of Hdac7 and Tcf7l2 in INS-1832/13 cells INS-1
832/13 beta cells were transfected with Hdac7 plasmid as
described above and cotransfected with small interfering
(si)RNAs targeting Hdac7 (siHdac7, 12.5 nmol/l) or Tcf7l2
( s i T c f 7 l 2 , 2 5 n m o l / l ) ( O N - TA R G E T p l u s
siRNA–SMARTpool; Dharmacon, Heidelberg, Germany)
using the DharmaFECT I siRNA Transfection Reagent
(Th e rmo Sc i e n t i f i c ) . A non - t a r g e t i n g s iRNA
(5ʹ-GAGACCCUAUCCGUGAUUAUU-3ʹ) was used as
118 Diabetologia (2017) 60:116–125
negative control. Silencing was validated by qPCR, as
described above.
Chromatin immunoprecipitation (ChIP) ChIP followed by
ChIP-qPCR was performed on Hdac7- and control-
transfected INS-1 832/13 beta cells to test for enrichment of
histone 3 lysine 27 acetylation (H3K27ac) at the Tcf7l2,
Gapdh and Ldha genes (see electronic supplementary material
[ESM] Methods and ESM Table 1).
Statistics RNA sequencing data were analysed using a
Mann–Whitney U test. Wilcoxon signed-rank tests were used
to analyse the rat islet and clonal beta cell data. False
discovery rate analysis was used to correct for multiple
testing.
Results
HDAC7 expression is increased in pancreatic islets from
human donors with type 2 diabetesUsing RNA sequencing,
we found increased HDAC7 expression in pancreatic islets
from donors with type 2 diabetes compared with non-
diabetic controls (Fig. 1a), confirming our previous finding
[3]. There were also significant differences in GSIS at
16.7 mmol/l glucose (p=0.05), HbA1c (p<0.0001) and BMI
(p = 0.03) between the non-diabetic and diabetic donors
(Table 1). However, there was no significant difference in
age (p=0.24) between the two groups. In addition, the expres-
sion level of HDAC7 correlated negatively with GSIS in hu-
man islets (r=–0.41, p<0.004).
Impaired GSIS in rat islets and clonal beta cells overex-
pressingHdac7 The expression data onHDAC7 from human
islets do not resolve whether changes are a primary or
secondary phenomenon. To address this question, and mimic
the situation in human type 2 diabetic islets, we overexpressed
Hdac7 in isolated rat islets and in INS-1 832/13 beta cells
(Fig. 1b–d). Increased HDAC7 expression resulted in reduced
GSIS at 16.7 mmol/l glucose in both rat islets and clonal beta
cells (Fig. 1e,f). In addition, Hdac7 overexpression had
nominal effects on insulin secretion in response to only the
membrane-depolarising agent KCl (p=0.054 at 2.8 mmol/l
glucose), but there was no effect on the basal secretion at
2.8 mmol/l glucose (Fig. 1f). Furthermore, the insulin content
was reduced inHdac7-overexpressing beta cells (Fig. 1g), but
unaffected in rat islets (data not shown).
Hdac7 overexpression impairs mitochondrial function A
possible explanation for the reduced GSIS in Hdac7-overex-
pressing beta cells is deficient mitochondrial function. Indeed,



































































































































































































Fig. 1 Hdac7 overexpression impaired insulin secretion and content. (a)
HDAC7 expression, as measured by RNA sequencing, was higher in
human pancreatic islets from donors with type 2 diabetes (n= 16) com-
pared with non-diabetic controls (n = 85). (b) Transduction of isolated rat
islets with an adenoviral vector encoding Hdac7 led to significant over-
expression of Hdac7mRNA. (c, d) Transfection of clonal beta cells with
a pcDNA3.1 expression plasmid containing Hdac7 resulted in elevated
mRNA (c) and protein (d) levels (n= 6 and n= 3, respectively). (e)Hdac7
overexpression in rat islets resulted in reduced GSIS (n= 6). White bars,
control; black bars, Hdac7. (f) Insulin secretion in response to 2.8 and
16.7 mmol/l glucose with or without depolarising concentrations of K+ in
clonal beta cells overexpressingHdac7 compared with control transfected
cells (n = 9). White bars, control; black bars, Hdac7. (g) Hdac7 overex-
pression resulted in reduced insulin content in clonal beta cells (n = 6).
Data are presented as means ± SEM. *p < 0.05, **p < 0.01. RNA se-
quencing data were analysed with a Mann–Whitney U test, and
Wilcoxon signed-rank tests were used to analyse the rat islet and clonal
beta cell data. HA-tag, haemagglutinin-tag; IB, immunoblot antibody;
T2D, type 2 diabetes
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to be reduced inHdac7-overexpressing cells (Fig. 2a, b). This
was reflected by reduced glucose-stimulated ATP levels in
these cells (Fig. 2c), as well as by reduced oligomycin-
sensitive respiration (i.e. ATP turnover; Fig. 2a).
Altered gene expression and cell number in beta cells over-
expressingHdac7 As HDAC7 may alter gene expression, we
investigated the genome-wide expression pattern in Hdac7-
overexpressing and control clonal INS-1 832/13 beta cells.
We found 1171 differentially expressed genes at p< 0.05
(548 genes upregulated and 623 genes downregulated), but
no individual gene, except Hdac7, had a false discovery rate
of less than 5% (ESM Table 2). However, based on the
impaired mitochondrial function in Hdac7-overexpressing
beta cells, we specifically examined whether the expression
of genes with known roles in mitochondrial metabolism was
decreased (p<0.05) in these cells. Indeed, Sdhc, Ndufa7 and
Atp5g3, which are involved in the tricarboxylic acid cycle and
the electron transport chain, exhibited decreased expression
(ESM Table 2). Furthermore, the expression of Pcsk1, which
is involved in the processing of proinsulin to insulin, was
slightly reduced in Hdac7-overexpressing cells.
To identify biological pathways with altered expression in
Hdac7-overexpressing beta cells, we next used GSEA. This
analysis yielded eight significant gene sets with down-
regulated expression in beta cells overexpressing Hdac7
(q< 0.05, Table 2). These included pathways involved in
DNA replication and repair, transcription and nucleotide
metabolism, as well as protein folding, sorting and
degradation. However, we found no significant gene sets with
upregulated expression.
In addition, Tcf7l2 was one of the most significant genes in
the microarray analysis andwas upregulated in beta cells over-
expressing Hdac7 (ESM Table 2). Interestingly, TCF7L2
single-nucleotide polymorphisms have shown the strongest
association with type 2 diabetes in genome-wide association
studies, and TCF7L2 has been proposed to regulate islet
function [21]. We used qPCR to technically validate the up-
regula t ion of Tcf7 l2 in RNA iso la ted f rom the
Hdac7-overexpressing beta cells used for the microarray
analysis (Fig. 3a). We could also biologically replicate these
data in a different set of transfected cells. (Fig. 3b). We next
tested whether restoring the expression of Tcf7l2 in
Hdac7-overexpressing cells, by cotransfecting these cells with
an siRNA against Tcf7l2, had any impact on insulin secretion.
Interestingly, knockdown of Tcf7l2 partially reversed the
insulin secretion impairment in Hdac7-overexpressing cells
(Fig. 3c, d).
Based on the altered expression of gene sets regulating
DNA replication and nucleotide metabolism, we next tested
whether beta cell proliferation and/or apoptosis were altered
when Hdac7 was overexpressed. Increased HDAC7 levels
slightly, but significantly, reduced the number of beta cells
(ESM Fig. 1a). Moreover, caspase-3 and -7 activity was
increased in Hdac7-overexpressing cells, reflecting increased
apoptosis, whereas BrdU-incorporation was unchanged,
suggesting that cell proliferation was not affected (ESM
Fig. 1b,c). In isolated rat islets, however, short-term
overexpression of Hdac7 did not result in enhanced apoptosis
(ESM Fig. 1d).
Histone acetylation To investigate whether histone
acetylation was affected by Hdac7 overexpression, we
performed ChIP for the H3K27ac mark, which is associated
with promoters and enhancer regions of active genes. We
performed ChIP-qPCR for Tcf7l2, as well as for Gapdh and
Ldha as positive and negative controls, respectively, since
Gapdh is highly expressed and Ldha is expressed at very
low levels, if at all, in beta cells. As expected, the Gapdh
promoter was highly enriched for H3K27ac, whereas the mark
was virtually absent in Ldha. There was no significant
di fference in H3K27ac enr ichment be tween the
Hdac7-overexpressing and control cells for Gapdh or Ldha




































































































Fig. 2 Hdac7 overexpression resulted in mitochondrial dysfunction. (a)
The OCR in clonal beta cells overexpressing Hdac7 and control cells
(n = 5). The OCR was measured in the presence of 2.8 mmol/l glucose
(basal respiration, BR) and then after the sequential addition of
16.7 mmol/l glucose (Glc; glucose-stimulated respiration, GSR),
4 μg/ml oligomycin (oligo), 4 μmol/l carbonyl cyanide p-
trifluoromethoxyphenylhydrazone (FCCP) and 1 μmol/l rotenone.
White circles, control; black squares, Hdac7. (b) The glucose-stimulated
OCR was significantly decreased in Hdac7-overexpressing beta cells
compared with control cells (n= 5). *p< 0.001 as analysed by a paired
t test. (c) Cellular ATP levels were reduced in Hdac7-overexpressing
clonal beta cells (n = 6). White bars, control; black bars, Hdac7. Data
are presented as means ± SEM. *p < 0.05, as analysed by Wilcoxon
signed-rank tests
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significant differences in H3K27ac enrichment between
control and Hdac7-overexpressing cells (ESM Fig. 2),
suggesting other regulatory mechanisms for the differential
Tcf7l2 expression.
HDAC7 inhibition restores GSIS in beta cells over-
express ing Hdac7 In an a t t empt to rescue the
Hdac7-associated beta cell dysfunction, and to test if
HDAC7 may be a potential target for novel type 2 diabetes
therapies, we treated Hdac7-overexpressing beta cells with
two different HDAC inhibitors: TSA (an inhibitor of class I
and class II HDACs) and MC1568 (an inhibitor of class II
HDACs) [16, 17]. TSA treatment nominally increased GSIS
in the beta cells transfected with the control vector
(p = 0.0625). However, the effect was greater on
Hdac7-overexpressing beta cells and the negative impact of
HDAC7 on GSIS was no longer apparent (Fig. 4a). MC1568
treatment also completely reversed the negative effect of
Hdac7 overexpression on GSIS, but without affecting insulin
secretion in the control cells (Fig. 4b).
Finally, as a more specific approach, we tested whether
cotransfecting the Hdac7-overexpressing cells with an
siRNA targetingHdac7 could rescue the secretory defect seen
in Fig. 1f. The siRNA resulted in 60% lower Hdac7 expres-
sion compared with cells transfected with the Hdac7 overex-
pression plasmid alone (Fig. 4c). This resulted in a partial
rescue of the decreased GSIS in Hdac7-overexpressing beta
Table 2 Genes contributing to the enrichment scores of GSEA for gene sets downregulated in Hdac7-overexpressing vs control beta cells
Gene set ID and
name










Dna2, Lig1,Mcm2,Mcm6,Mcm7, Pcna, Pola2, Pold2, Pole, Pole2, Prim2, Rfc2,
Rfc3, Rfc5, Rnaseh1, Rnaseh2a, Rpa1, Rpa2, Rpa3, Ssbp1
20/31 0.6334 <0.001 <0.001
RN03020 RNA
polymerase
Polr1a, Polr1b, Polr1c, Polr1e, Polr2a, Polr2b, Polr2c, Polr2e, Polr2f, Polr2i,
Polr3b, Polr3d, Polr3h, Polr3k
14/23 0.6838 <0.001 <0.001
RN03040
Spliceosome
Acin1, Alyref, Bcas2, Ccdc12, Cherp, Ddx23, Ddx39b, Ddx46, Dhx15, Dhx38,
Eftud2, Hnrnpu, Lsm3, Lsm4, Lsm5, Lsm6, Magoh, Magohb, Ncbp1, Phf5a,
Ppie, Ppih, Ppil1, Pqbp1, Prpf3, Prpf4, Prpf40a, Prpf8, Puf60, Rbm8a, Sf3a1,
Sf3a2, Sf3a3, Sf3b3, Sf3b4, Sf3b5, Slu7, Snrnp27, Snrnp40, Snrnp70, Snrpb,
Snrpd1, Snrpf, Srsf1, Srsf4, Srsf5, Srsf7, Srsf9, Thoc2, Thoc3, Usp39, Wbp11,
Zmat2
54/98 0.5070 <0.001 <0.001
RN03430 Mismatch
repair
Exo1, Lig1,Mlh1,Mlh3,Msh2, Pcna, Pold2, Rfc2, Rfc3, Rfc5, Rpa1, Rpa2, Rpa3,
Ssbp1
14/21 0.6394 <0.001 0.0024
RN03050
Proteasome
Psma1, Psma2, Psma5, Psma6, Psmb1, Psmb2, Psmb3, Psmb7, Psmc2, Psmc3,
Psmc5, Psmc6, Psmd1, Psmd2, Psmd3, Psmd11, Psmd12, Psmd13, Psmd14,
Shfm1




Ddb1, Ercc1, Gtf2h3, Gtf2h5, Pcna, Pole, Pole2, Rbx1, Rfc2, Rfc5, Rpa1, Rpa2,
Rpa3




Eme1, Mre11a, Mus81, Pold2, Rad51, Rad51c, Rad54b, Rpa1, Rpa2, Rpa3,
Shfm1, Ssbp1




Cad, Ctps1, Dck, Dtymk, Dut, Entpd5, Itpa, Nme1, Nme3, Nt5c1a, Nt5c3a, Nt5m,
Pola2, Pold2, Pole, Pole2, Polr1a, Polr1b, Polr1c, Polr1e, Polr2a, Polr2b,
Polr2c, Polr2e, Polr2f, Polr2i, Polr3b, Polr3d, Polr3h, Polr3k, Prim2, Rrm2,
Txnrd1, Tyms, Umps, Upb1







































































































































Fig. 3 Hdac7 overexpression impaired insulin secretion partly through
increased Tcf7l2 expression. qPCR was used to technically (a, n= 6) and
biologically (b, n = 4) validate the increased expression of Tcf7l2 in
Hdac7-overexpressing clonal beta cells. *p < 0.05. Silencing Tcf7l2 (c)
partially restored GSIS in Hdac7-overexpressing beta cells (d). White
bars, 2.8 mmol/l glucose; black bars, 16.7 mmol/l glucose; n = 6.
*p< 0.05 vs siRNA negative control (siNC); †p< 0.05 vs Hdac7 siNC.
Data are presented as means ± SEM
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cells (Fig. 4d). The fact that the rescue was not complete is
very likely explained by Hdac7 still being significantly
overexpressed compared with control transfected cells
(Fig. 4c).
Discussion
In this study, we have shown that HDAC7 is upregulat-
ed in type 2 diabetic human islets, and impairs insulin
secretion and mitochondrial function and induces apo-
ptosis when overexpressed in clonal beta cells.
Importantly, insulin secretion was restored when
Hdac7-overexpressing beta cells were treated with
HDAC inhibitors, supporting the use of such com-
pounds in the treatment of diabetes.
HDAC inhibitors are currently used for the treatment of
epilepsy and cancer [22, 23], and HDACs might also be
interesting pharmacological targets for type 2 diabetes.
Indeed, work from Mandrup-Poulsen and colleagues has
shown that several HDACs, including HDAC1–3, HDAC6
and HDAC11, regulate beta cell function [24–26]. Although
these studies imply that increased HDAC levels may
contribute to diabetes via hyperglycaemia and cytokine-
induced toxicity, they did not identify HDAC7 as a target for
the disease. Using microarray techniques, we recently found
decreased DNA methylation and increased expression of
HDAC7 in pancreatic islets from donors with type 2 diabetes
[3], supporting a possible role for this enzyme in beta cell
dysfunction and diabetes. Importantly, through the use of
RNA sequencing in a larger islet cohort, we also found
increased HDAC7 levels in diabetic islets in the present study.
We also found a negative correlation between HDAC7
expression and insulin secretion from human islets cultured
in vitro. Using functional experiments in clonal beta cells, we
could further dissect how HDAC7 contributes to impaired
insulin secretion. These experiments suggest that HDAC7 im-
pairs mitochondrial function, increases beta cell apoptosis and
increases Tcf7l2 expression. An impaired capacity to increase
ATP production in beta cells in response to elevated glucose
levels is indeed an important defect seen in diabetes, resulting
in reduced insulin secretion [27–29]. The effect of Hdac7
overexpression on mitochondrial function may be mediated
by the altered transcription of genes involved in metabolic
processes. Indeed, we found decreased expression of genes
involved in the tricarboxylic acid cycle and electron transport
chain. It could also be due to interactions with and/or
deacetylation of non-histone proteins affecting mitochondrial
function. For example, HDAC7 has been shown to interact
with and increase the transcriptional activity of hypoxia-
inducible factor 1α [30], a known regulator of mitochondrial
metabolism [31]. TCF7L2 is known as the ‘top’ diabetes gene,
and the genotype increasing the risk for type 2 diabetes is also
associated with increased TCF7L2 expression in human islets
[21]. Interestingly, in the current study we found reduced
insulin secretion and content in beta cells with increased
Hdac7 and Tcf7l2 levels. Our findings are also in line with
those of a previous study, showing that inhibition of HDACs
enhances mitochondrial function and oxidative metabolism in


















































































































































 mmol/l  mmol/l
Fig. 4 Inhibition of HDAC7 rescued impaired insulin secretion. (a) TSA
(0.625 μmol/l) restored GSIS in Hdac7-overexpressing clonal beta cells,
while the effect on control cells did not reach significance (p = 0.0625)
(n = 6). White bars, control; black bars, Hdac7. (b) MC1568 (1 μmol/l)
restored GSIS in Hdac7-overexpressing clonal beta cells (n= 6). White
bars, control; black bars, Hdac7. (c) Hdac7 silencing (60%) in
Hdac7-overexpressing clonal beta cells was confirmed by qPCR
(n = 6). (d) Silencing Hdac7 in cotransfected Hdac7-overexpressing beta
cells partially restored GSIS (n = 6). White bars, 2.8 mmol/l glucose;
black bars, 16.7 mmol/l glucose. Data are presented as means ± SEM.
*p< 0.05; †p< 0.05 vs Hdac7 siRNA negative control (siNC)
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number of functional beta cells can contribute to type 2
diabetes. Our data showing a decreased beta cell number due
to increased apoptosis with Hdac7 overexpression are also
supported by a previous study in cancer cells, which
demonstrated that ectopic expression of HDAC7 promotes
apoptosis and inhibits tumour growth [33].
In addition, there is evidence that HDACs may be promising
pharmacological targets inmultifactorial diseases [34]. To inves-
tigate if HDAC7 inhibition restores insulin secretion, we treated
Hdac7-overexpressing beta cells with two different HDAC in-
hibitors. Indeed, TSA treatment restored insulin secretion in
Hdac7-overexpressing beta cells. However, it also nominally
increased insulin secretion in control cells, potentially due to
effects on enzymes other than HDAC7. We therefore also used
MC1568, a selective inhibitor of class II HDACs [16].
Importantly, MC1568 restored insulin secretion in Hdac7-over-
expressing beta cells, but had no effect on control cells. These
experiments support the development of a HDAC7-specific
inhibitor for potential use in the treatment of diabetes.
The reduced methylation and increased expression of
HDAC7 seen in type 2 diabetic islets may be due to
environmental and/or genetic factors. We have previously
published studies on clonal beta cells and human islets treated
with elevated levels of palmitate (i.e. a type 2 diabetes-like
treatment), but found no differences in HDAC7 expression in
these studies [18, 35]. This does not, however, exclude
elevated palmitate levels as a cause of increased HDAC7
expression, as such changes may need longer than the 48 h
treatment we used to be established. Furthermore, we recently
performed a methylation quantitative trait loci study in human
pancreatic islets to identify genetic variants that influence
DNA methylation and expression [36]. However, we did not
find any single-nucleotide polymorphisms associated with
altered expression or methylation of HDAC7. Other
environmental factors may, however, alter the methylation
and expression of HDAC7 in islets.
In addition, the decreased methylation and increased
expression of HDAC7may occur as a result of environmental
insults during embryonic development. This may potentially
predispose individuals to diabetes by affecting the number of
beta and/or alpha cells in the mature pancreas. Interestingly, it
is known that the development of endocrine cells is controlled
by HDACs, and HDAC inhibition by TSA has been reported
to increase the number of neurogenin-3-expressing progenitor
cells [37]. In addition, selective inhibition of class IIa HDACs
(HDAC4, -5, -7 and -9) has been reported to increase the pool
of beta and delta cells [9].
Pancreatic islets contain cell types other than beta cells, and
it is possible that the increased expression of HDAC7 in
diabetic islets stems from differential expression of HDAC7
in the different islet cell types, in combination with altered
cellular composition of the islets. Unfortunately, to our
knowledge, no data that can conclusively resolve this issue
exists, and we have been unsuccessful in our attempts to
generate this type of data owing to limitations in islet material.
However, publicly available expression data on isolated
human alpha and beta cells, the two major islet cell types,
show that the expression of HDAC7 does not differ between
the two cell types [38], and our own published data found that
islet cell composition did not differ between diabetic and
non-diabetic donors in a subset of our cohort [3].
Furthermore, other HDACs may contribute to type 2 dia-
betes. In fact, the expression of HDAC1 and HDAC11 was
increased and decreased, respectively, in our previously
analysed cohort of islets from diabetic and control donors
(T. Dayeh and C. Ling, unpublished data). However, these
changes were of smaller relative magnitude compared with
the changes inHDAC7, and these enzymes have already been
somewhat investigated in beta cells [25, 26]. It is also possible
that increased HDAC7 levels may alter the expression of other
HDACs. In our Hdac7-overexpressing beta cells, we could
see that the expression of Hdac5 was slightly reduced
(p=0.045). The present study did not investigate whether this
has any functional effects on beta cells.
In conclusion, our study identifies HDAC7 as an enzyme
that regulates beta cell function and number, and which is
upregulated in human diabetic islets. It also supports further
development of HDAC7 inhibitors for diabetes therapy.
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